Expansion opportunities Thermo Fisher Scientific's PPD is expanding bioanalytical capabilities with a new laboratory in Gothenburg, Sweden, and is enhancing real-world data capabilities through collaboration with HealthVerity. This signals ongoing capacity growth and data-powered trial optimization opportunities for clients seeking global lab services and advanced data integration.

Data-driven trials Strategic data collaborations with HealthVerity to access large de-identified claims datasets indicate a strong emphasis on real-world data to augment clinical development and evidence generation, presenting a sales angle for clients prioritizing RWE-enabled trial design and post-market insights.

Comprehensive services PPD offers end-to-end clinical development support—from early to post-approval, patient recruitment, investigator sites, and laboratory services—enabling cross-sell to sponsors seeking a single integrated partner to streamline timelines and reduce vendor fragmentation.

Thermo Fisher backing As the clinical research business within Thermo Fisher Scientific, PPD benefits from strong corporate backing, scale, and technology investments, which can be leveraged in conversations about reliability, compliance, and access to broader Thermo Fisher capabilities.

Industry momentum Recent activity in biomedicine research and Alzheimer’s real-world evidence initiatives (CorEvitas registry) suggests increasing demand for real-world evidence, biomarker laboratories, and GLP-capable facilities, providing entry points for clients pursuing registry studies, biomarker workups, and post-approval studies.